Drug Trial Radar · NCT00767507
Maintenance of Platelet Inhibition With Cangrelor
Last checked: Nov 20, 2026Latest source record: Apr 4, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
221
Actual
Start
Oct 2008
Primary completion
Jun 2011
Study completion Jul 2011
Sponsor
- Lead sponsor
- The Medicines CompanyIndustry
- Sponsor type
- Industry
- First posted
- Oct 7, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate that patients receiving cangrelor infusion before coronary artery bypass grafting have an acceptable safety profile and can undergo surgery without excessive bleeding peri-operatively.
Conditions
- Acute Coronary Syndrome (ACS)
Interventions
cangrelorDrug
PlaceboOther
Placebo IV infusion administered in the same fashion as the active study drug in order to maintain the blind in the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stage I: Percentage of Patient Samples That Maintained Platelet Inhibition Levels of Greater Than or Equal to 60% as Reported by the VerifyNow P2Y12 Point of Care Assay.Time frame: During study drug infusion up to 1-6 hours prior to surgery
- Stage II: The Percentage of Patients That Maintained Platelet Reaction Units (PRU) < 240, as Determined by the VerifyNow P2Y12 Point of Care Assay, Measured During Study Drug Infusion Pre-surgery.Time frame: During study drug infusion up to 1-6 hours prior to surgery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Scripps Clinic / Scripps Green Hospital
La Jolla, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.